Table 1.
Pharmacological and safety characteristics of Covid-19 vaccines.
| Pfizer-BioNTech | Moderna | Astra-Zeneca | |
|---|---|---|---|
| Technology | mRNA | mRNA | Adenovirus |
| EMA approval | 21 December 2020 | 6 January 2021 | 31 January 2021 |
| Minimum age | 16 yrs | 18 yrs | 18 yrs |
| Schedule | 2 doses (30 μg) (0–21 days) | 2 doses (100 μg) (0–28 days) | Needs definition |
| Length of response | Unknown | Unknown | Unknown |
| In vitro development of Neutralizing ABs | Yes | Yes | Yes |
| Efficacy | Yes | Yes | Yes |
| 1. Prevention of symptomatic disease following 2° dose | 94.1% (95% CI, 89.3 - 96.8%) | 94.6% (95% CI, 89.9–97.3) | 70•4% (95% CI, 54.8–80.6) |
| 2. Prevention of transmission | Not Reported | Not Reported | Not Reported |
| Patients with liver disease enrolled in RCTs | N = 217 | N = 196 | Excluded |
| Patients who received OLT or on immunosuppressive therapies | Excluded | Excluded | Excluded |
Legend: EMA, European Medicine Agency; AB, antibody; RCT, randomized controlled trial; OLT, orthotopic liver transplantation.